MedTrace Logo

A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

NCT03714529 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-10-08

No results posted yet for this study

Summary

A single center, open-label, phase IIa, single arm, window of opportunity trial with IO103 and Montanide adjuvant in patients with surgically resectable BCC.

Conditions

Interventions

BIOLOGICAL

PD-L1

IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Herlev and Gentofte Hospital

    lead OTHER

Principal Investigators

  • Inge Marie Svane, Prof · Herlev and Gentofte Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-02-05
Completion
2020-02-05

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714529 on ClinicalTrials.gov